LAVA Therapeutics NV (LVTX)
2.67
-0.09
(-3.26%)
USD |
NASDAQ |
May 17, 16:00
2.67
0.00 (0.00%)
After-Hours: 20:00
LAVA Therapeutics Total Liabilities (Quarterly): 50.53M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 50.53M |
| September 30, 2023 | 56.42M |
| June 30, 2023 | 58.65M |
| March 31, 2023 | 60.00M |
| December 31, 2022 | 57.38M |
| September 30, 2022 | 57.23M |
| June 30, 2022 | 21.27M |
| Date | Value |
|---|---|
| March 31, 2022 | 21.10M |
| December 31, 2021 | 20.88M |
| September 30, 2021 | 22.54M |
| June 30, 2021 | 23.02M |
| March 31, 2021 | 28.32M |
| December 31, 2020 | 12.86M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
12.86M
Minimum
Dec 2020
60.00M
Maximum
Mar 2023
37.71M
Average
28.32M
Median
Mar 2021
Total Liabilities (Quarterly) Benchmarks
| uniQure NV | 623.30M |
| ProQR Therapeutics NV | 96.17M |
| Merus NV | 148.64M |
| argenx SE | -- |
| Pharming Group | 235.72M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 101.71M |
| Shareholders Equity (Quarterly) | 51.18M |
| Debt to Equity Ratio | 0.1032 |
| Current Ratio | 6.619 |
| Net Debt Paydown Yield | -0.53% |